Last Updated: November 16, 2026

Investigational Drug Information for IPI-549

« Back to Dashboard


What is the development status for investigational drug IPI-549?

IPI-549 is an investigational drug.

There have been 5 clinical trials for IPI-549. The most recent clinical trial was a Phase 1 trial, which was initiated on March 6th 2020.

The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Carcinoma, and Head and Neck Neoplasms. The leading clinical trial sponsors are Infinity Pharmaceuticals, Inc., Bristol-Myers Squibb, and Arcus Biosciences, Inc.

There are two hundred and four US patents protecting this investigational drug and three hundred and forty-nine international patents.

Recent Clinical Trials for IPI-549
TitleSponsorPhase
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaThe V Foundation for Cancer ResearchPhase 2
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaEzra CohenPhase 2
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)Roche Pharma AGPhase 2

See all IPI-549 clinical trials

Clinical Trial Summary for IPI-549

Top disease conditions for IPI-549
Top clinical trial sponsors for IPI-549

See all IPI-549 clinical trials

US Patents for IPI-549

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IPI-549 ⤷  Start Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
IPI-549 ⤷  Start Trial Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
IPI-549 ⤷  Start Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Start Trial
IPI-549 ⤷  Start Trial Crystalline forms of tenofovir alafenamide GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Start Trial
IPI-549 ⤷  Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
IPI-549 ⤷  Start Trial Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IPI-549

Drugname Country Document Number Estimated Expiration Related US Patent
IPI-549 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Start Trial
IPI-549 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26 ⤷  Start Trial
IPI-549 Australia AU2016322552 2035-09-14 ⤷  Start Trial
IPI-549 Canada CA2998469 2035-09-14 ⤷  Start Trial
IPI-549 China CN108349985 2035-09-14 ⤷  Start Trial
IPI-549 China CN114230571 2035-09-14 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

IPI-549 Eganelisib Development Update, Patent Position, FDA Status, and Market Projection

Last updated: September 8, 2026

IPI-549, also known as eganelisib, is an oral, selective phosphoinositide 3-kinase gamma, or PI3K-gamma, inhibitor developed by Infinity Pharmaceuticals for combination treatment in advanced solid tumors. Its clinical program has largely stalled after mixed results in the MARIO-3 study. IPI-549 has no FDA approval, no Orange Book listing, no commercial revenue, and no established generic or biosimilar entry pathway. Its near-term commercial value is therefore dependent on a third-party rescue, a new oncology combination strategy, or an out-licensing transaction.

What is IPI-549 and how does eganelisib work?

IPI-549 is designed to inhibit PI3K-gamma, an enzyme associated with immunosuppressive myeloid cells in the tumor microenvironment. The development thesis was that blocking PI3K-gamma could reprogram tumor-associated macrophages and improve the activity of immune checkpoint inhibitors such as nivolumab and atezolizumab.

The candidate was evaluated primarily in:

  • Triple-negative breast cancer, or TNBC
  • Renal cell carcinoma, or RCC
  • Other advanced solid tumors
  • Combination regimens involving checkpoint inhibitors and chemotherapy

IPI-549 is distinct from approved PI3K inhibitors such as alpelisib, idelalisib, duvelisib and inavolisib. Those products primarily target PI3K alpha, delta or broader pathway activity. IPI-549 was developed as a PI3K-gamma-selective immuno-oncology agent.

What is the current development status of IPI-549?

IPI-549 is not an approved medicine and does not have an active late-stage registration program publicly supporting a near-term launch.

Infinity’s central clinical program was the MARIO platform. MARIO-1 generated early evidence of clinical activity for IPI-549 in combination with nivolumab. The company then advanced MARIO-3, a randomized Phase 2 study testing IPI-549 in combination with atezolizumab and nab-paclitaxel in first-line metastatic TNBC, with an additional RCC cohort.

The development sequence is summarized below.

Period Development event Commercial relevance
2017-2019 Early clinical development and partnering activity Established IPI-549 as a clinical-stage PI3K-gamma program
2020 FDA Fast Track designation reported for an IPI-549 combination program Regulatory interaction accelerated, but did not establish approval eligibility
2020-2021 MARIO-3 Phase 2 enrollment and early readouts Early response data supported continued investigation
2021-2022 MARIO-3 data failed to establish a clear registrational path Reduced probability of near-term approval
2022 onward Clinical development deprioritized or discontinued in the disclosed program No public launch timeline or active pivotal program
Through 2024 No NDA, BLA, approval or commercial launch reported Revenue remains zero

Early MARIO-3 results indicated high response rates in treatment-naive TNBC, but subsequent development did not produce a sufficiently differentiated or durable clinical profile to support continued investment at the original scale. Infinity’s public disclosures indicated that the program was no longer being advanced as a primary clinical asset.

What were the MARIO-1 and MARIO-3 results?

MARIO-1 was an open-label Phase 1/2 study evaluating IPI-549 alone and in combination with nivolumab. The program generated evidence that IPI-549 could be administered with checkpoint blockade and showed signals of activity in selected tumor types.

MARIO-3 evaluated IPI-549 with atezolizumab and nab-paclitaxel in first-line metastatic TNBC. Publicly reported interim data showed a high objective response rate, but the durability and comparative benefit were not sufficient to create a clear path toward regulatory approval.

The principal development risks were:

  1. Lack of a confirmed survival advantage.
  2. Dependence on a complex triplet regimen.
  3. Competition from antibody-drug conjugates and other immuno-oncology combinations.
  4. Limited validation of PI3K-gamma inhibition as a broadly effective mechanism.
  5. Clinical development cost relative to the size of the addressable niche.

The program also faced the standard risk for tumor-microenvironment therapies: biomarker selection. Without a validated diagnostic identifying tumors dependent on PI3K-gamma-mediated immune suppression, clinical response rates may not translate across broad solid-tumor populations.

What is the FDA regulatory status of IPI-549?

IPI-549 has not received FDA approval. The FDA has not approved eganelisib for TNBC, RCC, melanoma, colorectal cancer or any other indication.

FDA status item IPI-549 position
FDA approval None
NDA or BLA approval None publicly reported
Fast Track designation Reported during development
Breakthrough Therapy designation No publicly confirmed designation
Priority Review None
FDA label None
REMS None
Orange Book listing None
Approved indication None

Fast Track designation does not confer approval, exclusivity or a guaranteed review outcome. If development resumes, the sponsor would likely need a new clinical strategy and a trial capable of demonstrating clinically meaningful benefit against current standards of care.

What patents protect IPI-549 and when could exclusivity expire?

IPI-549 is protected by composition-of-matter, pharmaceutical composition and method-of-use patent families associated with PI3K-gamma inhibition. Public corporate filings describe patent protection as extending into the early 2030s for certain rights, subject to jurisdiction, patent-term adjustment, patent-term extension and claim validity.

A precise single expiration date cannot be assigned to the entire IPI-549 estate because protection depends on the individual patent, claim scope and country. The practical patent position is:

Protection category Relevance
Composition of matter Core protection for eganelisib and related PI3K-gamma inhibitors
Pharmaceutical compositions Protection for formulations and dosage forms
Combination therapy Potential coverage for use with checkpoint inhibitors or chemotherapy
Method of treatment Indication-specific protection in solid tumors
Manufacturing processes Potential barrier to independent synthesis
Regulatory exclusivity None currently, because no FDA approval exists

No Orange Book-listed IPI-549 patents exist because the product has no approved FDA reference product. Paragraph IV litigation therefore cannot begin under the Hatch-Waxman framework unless IPI-549 is first approved and listed.

Patent risk remains more relevant to a potential licensee than to generic manufacturers. A new sponsor would need to determine whether composition claims remain enforceable, whether formulation or combination claims can support a future product, and whether the clinical program can generate new patent-term value through later-filed use patents.

Are there Paragraph IV challenges or patent lawsuits involving IPI-549?

No public Paragraph IV challenge has been reported for IPI-549. No established Abbreviated New Drug Application pathway exists because there is no approved reference product.

There is also no widely reported patent litigation involving a generic manufacturer challenging IPI-549 patents. Any historical corporate disputes involving development rights or licensing would be separate from Hatch-Waxman litigation and would not create a generic launch framework.

The lack of litigation is commercial rather than favorable. It reflects the absence of an approved product and a viable generic market.

Does IPI-549 face biosimilar risk?

IPI-549 is a small-molecule drug, not a biologic. Biosimilar regulation under the Biologics Price Competition and Innovation Act does not apply. If IPI-549 is approved, competition would arise through an ANDA or, depending on the product and regulatory strategy, a 505(b)(2) application.

The main post-approval risks would be:

  • Paragraph IV patent challenges
  • 505(b)(2) development using published clinical data
  • Follow-on products with alternative formulations
  • Competing PI3K or immuno-oncology mechanisms
  • Off-label substitution pressure only if payer and clinical adoption support it

Which companies are competing with IPI-549?

IPI-549 competes less with another PI3K-gamma drug than with multiple immuno-oncology approaches.

Competitive category Representative products or companies Competitive effect
PD-1 and PD-L1 inhibitors Merck, Bristol Myers Squibb, Roche Establish combination and first-line standards
Antibody-drug conjugates Gilead, AstraZeneca, Daiichi Sankyo, ImmunoGen assets Reduce demand for broad immunomodulatory combinations
PI3K pathway inhibitors Novartis, Bayer, Gilead, Secura Bio Validate pathway but create safety and differentiation concerns
Tumor-microenvironment agents Multiple private and public biotechnology companies Compete for the same immunosuppressive biology
Cellular and bispecific therapies Large oncology companies and emerging biotechs Increase treatment alternatives in advanced disease

IPI-549 would require a clearly superior efficacy or tolerability profile to displace established checkpoint inhibitor and antibody-drug conjugate regimens.

What is the commercial market projection for IPI-549?

IPI-549 has no current product revenue. Its commercial value is best modeled through probability-adjusted scenarios rather than a conventional launch forecast.

Base case: no commercial launch

The base case is continued non-commercial status through the medium term. Under this scenario:

  • Revenue remains $0.
  • No sales force or manufacturing network is built.
  • The asset has value mainly as a licensing or acquisition option.
  • Patent value declines as core terms approach expiration.
  • A new sponsor must fund clinical redevelopment.

Rescue-development case

If a partner restarts development in a biomarker-selected population, a niche launch could produce peak global sales of approximately $100 million to $300 million. This range assumes:

  • One approved indication
  • Use in combination with a checkpoint inhibitor
  • A restricted patient population
  • Annual net pricing roughly comparable with specialty oncology products
  • Limited uptake because of competing agents

Successful differentiated-combination case

A stronger outcome would require a reproducible survival benefit, a validated biomarker and a manageable safety profile. Under that scenario, peak sales could reach approximately $500 million to $1 billion, but this would require a new pivotal program and several years of development. The probability of this outcome is materially lower than the no-launch scenario based on the disclosed clinical trajectory.

Scenario Approximate peak sales Key requirement
No launch $0 Program remains inactive
Niche relaunch $100 million-$300 million Partnered development in a selected population
Broad oncology success $500 million-$1 billion Positive pivotal data and differentiated survival benefit

These estimates are directional commercial scenarios, not reported company guidance. The most important valuation variable is not the theoretical size of the TNBC or RCC market. It is whether PI3K-gamma inhibition can produce a clinically validated benefit that is distinct from existing immuno-oncology combinations.

What licensing deals affect IPI-549?

Infinity has historically used partnerships to advance IPI-549 and related oncology programs. Takeda was previously associated with the program through a strategic collaboration, but the asset did not progress to commercialization under that relationship.

The current commercial question is whether Infinity or its successor can secure a new partner. A potential transaction would likely be structured around:

  • Low upfront consideration
  • Development and regulatory milestones
  • Regional rights
  • Option-based financing
  • Access to historical clinical data
  • New studies in biomarker-defined solid tumors

The absence of an approved product and the stalled late-stage path would weigh heavily on upfront value. Any meaningful deal would probably depend on a partner identifying a new biological rationale or combination strategy.

How strong is the patent estate for IPI-549?

The estate has strategic value but limited standalone commercial strength. Composition-of-matter protection is the most important category, while method-of-use and combination claims could become more relevant if a new indication is identified.

Patent strength is reduced by four factors:

  1. No approved product currently supports Orange Book enforcement.
  2. Clinical development has not established a durable commercial indication.
  3. Later-filed use patents would expire later but would depend on new clinical data.
  4. Competitors may avoid the claims through different PI3K-gamma chemotypes or alternative mechanisms.

The estate is therefore stronger as an asset supporting optionality than as a current barrier to market entry.

Key Takeaways

  • IPI-549, or eganelisib, is an oral selective PI3K-gamma inhibitor from Infinity Pharmaceuticals.
  • The candidate has no FDA approval, no Orange Book listing and no commercial revenue.
  • MARIO-3 generated early response signals but did not establish a durable registrational path.
  • No Paragraph IV challenge, biosimilar pathway or active generic litigation has been reported.
  • Patent protection is expected to extend into the early 2030s for certain rights, but expiration varies by patent and jurisdiction.
  • The base commercial forecast is $0 without a development restart.
  • A partnered niche launch could support peak sales of $100 million to $300 million.
  • Sales above $500 million would require a validated biomarker, positive pivotal data and a clear advantage over checkpoint inhibitors and antibody-drug conjugates.

FAQs

Is IPI-549 still in clinical development?

The publicly disclosed clinical program is not advancing toward an imminent approval. A new sponsor would likely need to restart or redesign development.

What is the generic name of IPI-549?

The nonproprietary name is eganelisib.

Does IPI-549 have an FDA approval date?

No. Eganelisib has no FDA approval date and no approved label.

Is IPI-549 a PI3K inhibitor like alpelisib?

Yes, but it is mechanistically distinct. IPI-549 selectively targets PI3K-gamma, whereas alpelisib primarily targets PI3K-alpha.

Can a generic company file an ANDA for IPI-549?

Not currently through the ordinary commercial pathway because no FDA-approved IPI-549 reference product exists. An ANDA strategy would become relevant only after approval of a reference product and listing of applicable patents.

References

  1. ClinicalTrials.gov. (2024). Study of IPI-549 in combination with nivolumab in patients with advanced solid tumors: MARIO-1. U.S. National Library of Medicine.

  2. ClinicalTrials.gov. (2024). Study of IPI-549 in combination with atezolizumab and nab-paclitaxel in patients with metastatic triple-negative breast cancer: MARIO-3. U.S. National Library of Medicine.

  3. Infinity Pharmaceuticals, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

  4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

  5. U.S. Food and Drug Administration. (2024). Fast Track designation and development programs. FDA.

  6. Infinity Pharmaceuticals, Inc. (2021). Corporate presentation and clinical development update for eganelisib. Infinity Pharmaceuticals.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.